Position
Fidelity in Acumen Pharmaceuticals, Inc.
Back to the book · All holders of ABOS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $2.34K$2.36 → $2.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.03M | $4.28M | — | — | — | 0.0% |
| Q1 2026 | 1.16M | $2.73M | $2.36 | $289.3K | −$1.84M | 0.0% |
| Q2 2026 | 7.53K | $20.1K | $2.67 | $2.34K | −$2.71M | 0.0% |